Metastatic Non-Squamous Non-Small Cell Lung Cancer
Oncology
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
5 drugs in development·5 companies·2 clinical trials
Drug Pipeline by Phase
Approved(3)
Phase 3(1)
| Drug | Company |
|---|---|
| abp 234 | AMGEN INC (AMGN) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| sitravatinib | Mirati Therapeutics, Inc. (MRTX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Metastatic Non-Squamous Non-Small Cell Lung Cancer?
BioSniper tracks 5 drugs in development for Metastatic Non-Squamous Non-Small Cell Lung Cancer across 5 companies.
How many clinical trials target Metastatic Non-Squamous Non-Small Cell Lung Cancer?
There are 2 clinical trials targeting Metastatic Non-Squamous Non-Small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Metastatic Non-Squamous Non-Small Cell Lung Cancer?
The estimated prevalence of Metastatic Non-Squamous Non-Small Cell Lung Cancer is approximately 75.0 per 100,000 population.
Deep-dive into Metastatic Non-Squamous Non-Small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis